Stocktoria
Edgewise Therapeutics, Inc. EWTX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-03-26
Edgewise Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $151.4M | $127.0M | $90.9M | $54.0M | $32.2M |
| Operating income | -$191.4M | -$158.8M | -$114.4M | -$71.7M | -$43.2M |
| Income tax | $4,000 | $3,000 | $4,000 | $0 | $0 |
| Net income | -$167.8M | -$133.8M | -$100.2M | -$67.6M | -$42.8M |
| EPS (diluted) | $-1.63 | $-1.45 | $-1.57 | $-1.26 | $-1.14 |
| Operating cash flow | -$143.8M | -$109.0M | -$91.9M | -$52.6M | -$33.5M |
| Free cash flow | -$144.1M | -$110.3M | -$97.7M | -$58.2M | -$34.2M |
| Cash & equivalents | $61.1M | $41.7M | $86.1M | $22.0M | $15.6M |
| Total assets | $552.6M | $486.8M | $340.0M | $367.1M | $285.2M |
| Total liabilities | $30.3M | $27.6M | $21.2M | $20.4M | $10.8M |
| Shareholders' equity | $522.3M | $459.2M | $318.8M | $346.7M | $274.4M |
Source: SEC EDGAR filings · CIK 0001710072 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.